Clinical Study

Mediteanox® and Pomanox®: Cardiovascular Health evidence

Format: PDF file | Document type: Clinical Study | Promoted Content

This content is provided by Euromed S.A., and any views and opinions expressed do not necessarily reflect those of

Mediteanox® and Pomanox®: Cardiovascular Health evidence

A Spanish Government-supported 20 week clinical trial investigated properties of heart-friendly Mediterranean diet olive and pomegranate polyphenols (Mediteanox®​ and Pomanox®​) on early atherosclerosis markers in 67 seemingly healthy participants.

From the results of the authoritative study, Dr Quirós-Fernández and co-authors conclude that standardized amounts of polyphenols as Pomanox®​ and Mediteanox®​, improved endothelial function, blood pressure and circulating oxLDL, especially in subjects with altered parameters.

According to the authors, regular intake may help reduce cardiovascular risk.

Related resources from Euromed S.A.

Supplier info centre